← boardnext 2033-08
SPRB
Spruce Biosciencesdistress 7/10 · high distress / dilution risk$43.91-2%today-94% from 52w high
Nephrology 1
Lead: MPS IIIB
Revenue
pre-revenue
Liquidity
$54M
Runway
1.8 yrs
Shares 1y
+389%
Price & events
-48.5% over 6M
CatalystRating changeDilutionFinancingdashed = today
-1.5%
1D
-0.8%
1W
-15.8%
1M
-18.7%
3M
-46.1%
6M
-93.7%
1Y
-98.5%
2Y
-99.9%
5Y
-100.0%
All
Overview
- Market Cap
- $120.85M
- Enterprise Value
- $72.24M
- Volume
- 4.50K
- 52 Week Range
- $7.00 – $698
- Total Shares
- 2.75M
- Float Shares
- 2.65M
- Short %
- 13.19%
- % Held by Insiders
- 3.52%
- % Held by Institutions
- 31.33%
- RVOL
- 0.06x
- Beta
- 3.21
Pipeline stages · 2 programs
Tralesinidase alfa (TA)
Preclin›
Ph1›
Ph2›
Ph3›
Filed›
PDUFA›
Approved
Tildacerfont
Preclin›
Ph1›
Ph2›
Ph3›
Filed›
PDUFA›
Approved
Pipeline · 2 trials · 1 upcoming
| Readout | Phase | Drug | Indication | Enroll | Status |
|---|---|---|---|---|---|
| 2033-08 Estimated 50% readout ~2033-10-15 | Phase 3 | Tralesinidase alfa (TA)fast trackrare pediatricorphan | MPS IIIB | — | not yet recruiting |
| 2025-01-31 | Phase 2 | Tildacerfont | Congenital Adrenal Hyperplasia, 21-OHD | 67 | terminated |
Catalyst news & presentations · 3
- first half of 2026regulatory submissionFiled (NDA/BLA)tralesinidase alfa · BLA submission to FDA for accelerated approval based on HS-NRE biomarkerSEC 8-K
- first quarter of 2026regulatory submissionFiled (NDA/BLA)tralesinidase alfa · Biologics License Application submission for TA-ERTSEC 8-K
- 2024-12-10trial discontinuedtildacerfont · CAHmelia-204 and CAHptain-205 clinical trials discontinued; company winding down investment in tildacerfont for CAH.SEC 8-K
Approved drugs (0)
- none — clinical-stage
Capital structure — dilution & financing
🔒 Top holders — Pro
Institutional ownership + quarter-over-quarter accumulation/trimming.
Upgrade to ProWall St ratings
strong buy · target $151 (+244% upside) · 8 analysts
- 2026-07-13B. Riley SecuritiesBuy
- 2026-06-16GuggenheimBuy
- 2026-06-09Jones TradingBuy
- 2026-06-01HC Wainwright & Co.Buy
- 2026-05-14CitizensMarket Outperform
- 2026-04-27Craig-HallumBuy
Competitors — MPS IIIB
- none identified
Recent news
- 2026-07-20Certain Restrcied Stock Units of Spruce Biosciences, Inc. are subject to a Lock-Up Agreement Ending on 20-JUL-2026. - marketscreener.com
- 2026-07-19Spruce Biosciences (SPRB) Corporate presentation Summary - Quartr
- 2026-07-18Spruce Biosciences (SPRB) AGM 2026 Summary - Quartr
- 2026-07-15Spruce Biosciences Announces Long-Term Tralesinidase Alfa Enzyme - The National Law Review
- 2026-07-15Spruce Biosciences Announces Long-Term Tralesinidase Alfa Enzyme - The National Law Review
- 2026-07-13SPRB Initiates Coverage On B. Riley Securities -- Buy Rating Ass - GuruFocus
- 2026-07-13B.Riley initiates Spruce Biosciences stock with buy rating on therapy potential - Investing.com
- 2026-07-09Spruce Biosciences (SPRB) CEO adds 266 shares through employee stock purchase plan - Stock Titan
Not financial advice. Data: ClinicalTrials.gov, SEC EDGAR, FINRA, Nasdaq, Yahoo.